Latest News

Novel Clinic Resulted in ‘Impressive’ Outcomes for Patients With Moderate to Severe Eczema


 

FROM PEDIATRIC DERMATOLOGY

Important model of care

Asked to comment on the results, pediatric dermatologist Moise L. Levy, MD, professor of internal medicine and pediatrics at the University of Texas at Austin, who was not involved with the study, characterized the MADP as an important model of care. “Multi-interdisciplinary care of such conditions is well-known to be of great help for patients and their families,” he told this news organization.

Dr. Moise L. Levy professor of pediatrics and medicine at the University of Texas at Austin Dell Medical Schoo

Dr. Moise L. Levy

“A key part of the ‘team’ is the family/patient engagement and shared decision-making. The use of visual aides to highlight components of care was likely of great use, as well,” he said. “All such interventions impact the disease, as well as associated problems, such as itch, sleep, and mental health. Importantly, such interventions, while known to be useful as demonstrated by the authors, take time, and relate to improved outcomes as noted by the date outlined by the authors.”

The study authors acknowledged certain limitations of the study, including the lack of a control group with single-specialty visits. “The real take-away is that taking the time to do more holistic assessments of health — with skin and allergy issues being discussed, and consistent education and messaging — helps make our medical interventions more successful, with both objective disease improvement and patient/family satisfaction,” Dr. Eichenfield said in the interview.

Pfizer and Sanofi provided financial support to MADP, and for the study. Dr. Eichenfield disclosed that he serves as a scientific adviser, consultant, and/or clinical trial investigator for AbbVie, Amgen, Aslan, Castle Biosciences, Dermavant, Eli Lilly and Company, Forté, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Trialspark, and UCB. Dr. Geng disclosed ties with Sanofi, Regeneron, Pfizer, and AbbVie, and is an adviser to Incyte, Galderma, Eli-Lilly, and LEO. The other authors reported having no disclosures. Dr. Levy disclosed ties with Abeona, Amgen, Arcutis, Castle Creek, Dusa Pharma, Krystal Bio, Novan, Regeneron, and Sanofi Genzyme. He is also an investigator for Janssen.

Pages

Recommended Reading

Paradoxical Eczema Risk Low With Biologic Psoriasis Treatments
MDedge Pediatrics
‘Real-World’ Registry Study of Upadacitinib Supports Clinical Trial Data
MDedge Pediatrics
What’s the Real Prevalence of Conjunctivitis in AD Patients Treated With Dupilumab?
MDedge Pediatrics
‘Milestone’ Study Zeros in on 5-Year Safety Data From Upadacitinib Trials
MDedge Pediatrics
Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options
MDedge Pediatrics
Experimental Topical Drug Shows Promise for Atopic Dermatitis and Plaque Psoriasis
MDedge Pediatrics
Which Tools Are Best to Streamline In-Office Assessments of Eczema Patients?
MDedge Pediatrics
US Dermatologic Drug Approvals Rose Between 2012 and 2022
MDedge Pediatrics
Expert Highlights Biologics in the Pipeline for Atopic Dermatitis
MDedge Pediatrics
AAAAI/ACAAI Joint Task Force Issues Updated ‘Practice-Changing’ Guidelines to Manage AD
MDedge Pediatrics